Payment overview · 2025
General Payments
$507.58
13 reported records · 4 companies
Healthcare provider profile · identity verified
Jerome Antony, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1639122583
Verified facts
What the public records show
CMS Open Payments records show Jerome Antony, M.D. received $507.58 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $251.64 | 49.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $173.59 | 34.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.10 | 13.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.25 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $507.58 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $220.33 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $117.36 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.22 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $66.10 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.36 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1058 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 836 | 134 |
| Gabapentin | Gabapentin | 326 | 57 |
| Furosemide | Furosemide | 314 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 46 |
| Donepezil Hcl | Donepezil Hcl | 306 | 22 |
| Trazodone Hcl | Trazodone Hcl | 295 | 36 |
| Eliquis | Apixaban | 263 | 25 |
| Metformin Hcl | Metformin Hcl | 263 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 38 |
| Lisinopril | Lisinopril | 241 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 46 |
| Losartan Potassium | Losartan Potassium | 222 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 217 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 25 |
| Buspirone Hcl | Buspirone Hcl | 191 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 191 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 12 |
| Famotidine | Famotidine | 188 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 49 |
| Levetiracetam | Levetiracetam | 185 | 16 |
| Spironolactone | Spironolactone | 184 | 15 |
| Potassium Chloride | Potassium Chloride | 181 | 30 |
| Carvedilol | Carvedilol | 171 | 24 |
| Omeprazole | Omeprazole | 156 | 15 |
| Memantine Hcl | Memantine Hcl | 146 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 15 |
| Meloxicam | Meloxicam | 110 | 25 |
| Nifedipine Er | Nifedipine | 110 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | suppressed |
| Ibuprofen | Ibuprofen | 106 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 89 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 86 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 16 |
| Xarelto | Rivaroxaban | 85 | suppressed |
| Simvastatin | Simvastatin | 84 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 81 | 14 |
| Jardiance | Empagliflozin | 79 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 78 | 12 |
| Azithromycin | Azithromycin | 76 | 57 |
| Amoxicillin | Amoxicillin | 74 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 22 |
| Risperidone | Risperidone | 70 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 13 |
| Atenolol | Atenolol | 66 | suppressed |
| Bumetanide | Bumetanide | 65 | suppressed |
| Latanoprost | Latanoprost | 64 | suppressed |
| Olanzapine | Olanzapine | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 58 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | suppressed |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Allopurinol | Allopurinol | 53 | 14 |
| Azelastine Hcl | Azelastine Hcl | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 28 |
| Lactulose | Lactulose | 52 | suppressed |
| Chlorthalidone | Chlorthalidone | 50 | suppressed |
| Prednisone | Prednisone | 50 | 16 |
| Methimazole | Methimazole | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 40 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Colchicine | Colchicine | 43 | suppressed |
| Naproxen | Naproxen | 43 | 11 |
| Finasteride | Finasteride | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 20 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 16 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 32 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 14 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 19 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Econazole Nitrate | Econazole Nitrate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Desonide | Desonide | 12 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $507.58 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, KISUNLA, MOUNJARO, REXULTI, TZIELD, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error